DOI record:
{
"DOI": "10.1016/s1473-3099(22)00507-2",
"ISSN": [
"1473-3099"
],
"URL": "http://dx.doi.org/10.1016/S1473-3099(22)00507-2",
"alternative-id": [
"S1473309922005072"
],
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "The Lancet Infectious Diseases"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/S1473-3099(22)00507-2"
},
{
"label": "CrossRef DOI link to the associated document",
"name": "associatedlink",
"value": "https://doi.org/10.1016/S1473-3099(22)00522-9"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2022 Elsevier Ltd. All rights reserved."
}
],
"author": [
{
"affiliation": [],
"family": "Wong",
"given": "Carlos K H",
"sequence": "first"
},
{
"affiliation": [],
"family": "Au",
"given": "Ivan C H",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Lau",
"given": "Kristy T K",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Lau",
"given": "Eric H Y",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Cowling",
"given": "Benjamin J",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Leung",
"given": "Gabriel M",
"sequence": "additional"
}
],
"container-title": "The Lancet Infectious Diseases",
"container-title-short": "The Lancet Infectious Diseases",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinicalkey.fr",
"clinicalkey.jp",
"clinicalkey.es",
"clinicalkey.com.au",
"clinicalkey.com",
"em-consulte.com",
"thelancet.com",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2022,
8,
24
]
],
"date-time": "2022-08-24T22:34:53Z",
"timestamp": 1661380493000
},
"deposited": {
"date-parts": [
[
2022,
8,
24
]
],
"date-time": "2022-08-24T22:35:19Z",
"timestamp": 1661380519000
},
"indexed": {
"date-parts": [
[
2022,
8,
24
]
],
"date-time": "2022-08-24T23:12:45Z",
"timestamp": 1661382765673
},
"is-referenced-by-count": 1,
"issued": {
"date-parts": [
[
2022,
8
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2022,
8,
1
]
],
"date-time": "2022-08-01T00:00:00Z",
"timestamp": 1659312000000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S1473309922005072?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"prefix": "10.1016",
"published": {
"date-parts": [
[
2022,
8
]
]
},
"published-print": {
"date-parts": [
[
2022,
8
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.3389/fphar.2022.816429",
"article-title": "Effectiveness of antiviral therapy in highly-transmissible variants of SARS-CoV-2: a modeling and simulation study",
"author": "Schöning",
"doi-asserted-by": "crossref",
"journal-title": "Front Pharmacol",
"key": "10.1016/S1473-3099(22)00507-2_bib5",
"volume": "13",
"year": "2022"
},
{
"DOI": "10.1016/j.dsx.2022.102396",
"article-title": "An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19",
"author": "Singh",
"doi-asserted-by": "crossref",
"journal-title": "Diabetes Metab Syndr",
"key": "10.1016/S1473-3099(22)00507-2_bib6",
"volume": "16",
"year": "2022"
},
{
"DOI": "10.3389/fimmu.2022.855496",
"article-title": "Molnupiravir and its antiviral activity against COVID-19",
"author": "Tian",
"doi-asserted-by": "crossref",
"journal-title": "Front Immunol",
"key": "10.1016/S1473-3099(22)00507-2_bib7",
"volume": "13",
"year": "2022"
},
{
"DOI": "10.1136/bmj.o443",
"article-title": "Molnupiravir's authorisation was premature",
"author": "Brophy",
"doi-asserted-by": "crossref",
"first-page": "o443",
"journal-title": "BMJ",
"key": "10.1016/S1473-3099(22)00507-2_bib8",
"volume": "376",
"year": "2022"
},
{
"article-title": "COVID-19: FDA expert panel recommends authorising molnupiravir but also voices concerns",
"author": "Dyer",
"journal-title": "BMJ",
"key": "10.1016/S1473-3099(22)00507-2_bib9",
"volume": "375",
"year": "2021"
},
{
"DOI": "10.1136/bmj.o977",
"article-title": "Imbalance in baseline characteristics in molnupiravir trials",
"author": "Hama",
"doi-asserted-by": "crossref",
"first-page": "o977",
"journal-title": "BMJ",
"key": "10.1016/S1473-3099(22)00507-2_bib10",
"volume": "377",
"year": "2022"
},
{
"DOI": "10.1016/S1473-3099(22)00119-0",
"article-title": "Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach",
"author": "Dal-Ré",
"doi-asserted-by": "crossref",
"first-page": "e231",
"journal-title": "Lancet Infect Dis",
"key": "10.1016/S1473-3099(22)00507-2_bib11",
"volume": "22",
"year": "2022"
},
{
"DOI": "10.1016/j.eclinm.2021.100743",
"article-title": "Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: a propensity-score analysis",
"author": "Wong",
"doi-asserted-by": "crossref",
"journal-title": "EClinicalMedicine",
"key": "10.1016/S1473-3099(22)00507-2_bib12",
"volume": "32",
"year": "2021"
},
{
"DOI": "10.1016/S1473-3099(22)00345-0",
"article-title": "Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study",
"author": "McMenamin",
"doi-asserted-by": "crossref",
"journal-title": "Lancet Infect Dis",
"key": "10.1016/S1473-3099(22)00507-2_bib13",
"year": "2022"
},
{
"DOI": "10.1001/jamainternmed.2020.6252",
"article-title": "Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19",
"author": "Gupta",
"doi-asserted-by": "crossref",
"first-page": "41",
"journal-title": "JAMA Intern Med",
"key": "10.1016/S1473-3099(22)00507-2_bib17",
"volume": "181",
"year": "2021"
},
{
"DOI": "10.1186/s13054-020-03422-3",
"article-title": "Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study",
"author": "Monedero",
"doi-asserted-by": "crossref",
"first-page": "2",
"journal-title": "Crit Care",
"key": "10.1016/S1473-3099(22)00507-2_bib18",
"volume": "25",
"year": "2021"
},
{
"DOI": "10.1093/aje/kwab028",
"article-title": "Biases in evaluating the safety and effectiveness of drugs for the treatment of COVID-19: designing real-world evidence studies",
"author": "Renoux",
"doi-asserted-by": "crossref",
"first-page": "1452",
"journal-title": "Am J Epidemiol",
"key": "10.1016/S1473-3099(22)00507-2_bib19",
"volume": "190",
"year": "2021"
},
{
"DOI": "10.1093/cid/ciab631",
"article-title": "Clinical improvement, outcomes, antiviral activity, and costs associated with early treatment with remdesivir for patients with coronavirus disease 2019 (COVID-19)",
"author": "Wong",
"doi-asserted-by": "crossref",
"first-page": "1450",
"journal-title": "Clin Infect Dis",
"key": "10.1016/S1473-3099(22)00507-2_bib20",
"volume": "74",
"year": "2022"
},
{
"DOI": "10.1002/sim.4067",
"article-title": "Multiple imputation using chained equations: issues and guidance for practice",
"author": "White",
"doi-asserted-by": "crossref",
"first-page": "377",
"journal-title": "Stat Med",
"key": "10.1016/S1473-3099(22)00507-2_bib22",
"volume": "30",
"year": "2011"
},
{
"DOI": "10.1177/0962280217713032",
"article-title": "Propensity score analysis with partially observed covariates: how should multiple imputation be used?",
"author": "Leyrat",
"doi-asserted-by": "crossref",
"first-page": "3",
"journal-title": "Stat Methods Med Res",
"key": "10.1016/S1473-3099(22)00507-2_bib23",
"volume": "28",
"year": "2019"
},
{
"DOI": "10.1002/bimj.200810488",
"article-title": "Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations",
"author": "Austin",
"doi-asserted-by": "crossref",
"first-page": "171",
"journal-title": "Biom J",
"key": "10.1016/S1473-3099(22)00507-2_bib24",
"volume": "51",
"year": "2009"
},
{
"DOI": "10.1093/cid/ciac180",
"article-title": "Molnupiravir and nirmatrelvir–ritonavir: oral COVID antiviral drugs",
"author": "Saravolatz",
"doi-asserted-by": "crossref",
"journal-title": "Clin Infect Dis",
"key": "10.1016/S1473-3099(22)00507-2_bib25",
"year": "2022"
},
{
"DOI": "10.1056/NEJMoa2118542",
"article-title": "Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19",
"author": "Hammond",
"doi-asserted-by": "crossref",
"first-page": "1397",
"journal-title": "N Engl J Med",
"key": "10.1016/S1473-3099(22)00507-2_bib27",
"volume": "386",
"year": "2022"
},
{
"DOI": "10.1056/NEJMoa2116044",
"article-title": "Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients",
"author": "Jayk Bernal",
"doi-asserted-by": "crossref",
"first-page": "509",
"journal-title": "N Engl J Med",
"key": "10.1016/S1473-3099(22)00507-2_bib28",
"volume": "386",
"year": "2022"
},
{
"article-title": "Effectiveness of paxlovid in reducing severe COVID-19 and mortality in high risk patients",
"author": "Najjar-Debbiny",
"journal-title": "Clin Infect Dis",
"key": "10.1016/S1473-3099(22)00507-2_bib29",
"year": "2022"
},
{
"article-title": "Oral nirmatrelvir and severe COVID-19 outcomes during the omicron surge",
"author": "Arbel",
"journal-title": "Research Square",
"key": "10.1016/S1473-3099(22)00507-2_bib30",
"year": "2022"
},
{
"DOI": "10.1056/EVIDoa2100044",
"article-title": "Randomized trial of molnupiravir or placebo in patients hospitalized with COVID-19",
"author": "Arribas",
"doi-asserted-by": "crossref",
"journal-title": "NEJM Evidence",
"key": "10.1016/S1473-3099(22)00507-2_bib31",
"volume": "1",
"year": "2022"
},
{
"DOI": "10.7326/M22-0729",
"article-title": "Effect of molnupiravir on biomarkers, respiratory interventions, and medical services in COVID-19: a randomized, placebo-controlled trial",
"author": "Johnson",
"doi-asserted-by": "crossref",
"journal-title": "Ann Intern Med",
"key": "10.1016/S1473-3099(22)00507-2_bib32",
"year": "2022"
},
{
"DOI": "10.1038/s41422-022-00619-9",
"article-title": "Reduced interferon antagonism but similar drug sensitivity in omicron variant compared to delta variant of SARS-CoV-2 isolates",
"author": "Bojkova",
"doi-asserted-by": "crossref",
"first-page": "319",
"journal-title": "Cell Res",
"key": "10.1016/S1473-3099(22)00507-2_bib33",
"volume": "32",
"year": "2022"
},
{
"DOI": "10.1038/s41422-022-00618-w",
"article-title": "SARS-CoV-2 omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination",
"author": "Li",
"doi-asserted-by": "crossref",
"first-page": "322",
"journal-title": "Cell Res",
"key": "10.1016/S1473-3099(22)00507-2_bib34",
"volume": "32",
"year": "2022"
},
{
"DOI": "10.1056/NEJMc2119407",
"article-title": "Efficacy of antibodies and antiviral drugs against COVID-19 omicron variant",
"author": "Takashita",
"doi-asserted-by": "crossref",
"first-page": "995",
"journal-title": "N Engl J Med",
"key": "10.1016/S1473-3099(22)00507-2_bib35",
"volume": "386",
"year": "2022"
},
{
"DOI": "10.1016/j.antiviral.2022.105252",
"article-title": "Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 omicron and other variants of concern",
"author": "Vangeel",
"doi-asserted-by": "crossref",
"journal-title": "Antiviral Res",
"key": "10.1016/S1473-3099(22)00507-2_bib36",
"volume": "198",
"year": "2022"
},
{
"DOI": "10.1016/j.bmcl.2022.128629",
"article-title": "Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir",
"author": "Ullrich",
"doi-asserted-by": "crossref",
"journal-title": "Bioorg Med Chem Lett",
"key": "10.1016/S1473-3099(22)00507-2_bib37",
"volume": "62",
"year": "2022"
},
{
"DOI": "10.1056/NEJMc2201933",
"article-title": "Efficacy of antiviral agents against the SARS-CoV-2 omicron subvariant BA.2",
"author": "Takashita",
"doi-asserted-by": "crossref",
"first-page": "1475",
"journal-title": "N Engl J Med",
"key": "10.1016/S1473-3099(22)00507-2_bib38",
"volume": "386",
"year": "2022"
},
{
"key": "10.1016/S1473-3099(22)00507-2_bib39",
"series-title": "Hetero announces interim clinical results from phase III clinical trials of molnupiravir conducted in India",
"year": "2021"
},
{
"DOI": "10.1126/scitranslmed.abl7430",
"article-title": "A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus",
"author": "Fischer",
"doi-asserted-by": "crossref",
"journal-title": "Sci Transl Med",
"key": "10.1016/S1473-3099(22)00507-2_bib40",
"volume": "14",
"year": "2022"
},
{
"DOI": "10.3389/fphar.2022.939573",
"article-title": "Antiviral efficacy and safety of molnupiravir against omicron variant infection: a randomized controlled clinical trial",
"author": "Zou",
"doi-asserted-by": "crossref",
"journal-title": "Front Pharmacol",
"key": "10.1016/S1473-3099(22)00507-2_bib42",
"volume": "13",
"year": "2022"
},
{
"article-title": "Oral antivirals for the prevention and treatment of SARS-CoV-2 infection",
"author": "Soriano",
"first-page": "41",
"journal-title": "AIDS Rev",
"key": "10.1016/S1473-3099(22)00507-2_bib43",
"volume": "24",
"year": "2022"
},
{
"DOI": "10.1016/j.dsx.2021.102329",
"article-title": "Molnupiravir in COVID-19: a systematic review of literature",
"author": "Singh",
"doi-asserted-by": "crossref",
"journal-title": "Diabetes Metab Syndr",
"key": "10.1016/S1473-3099(22)00507-2_bib46",
"volume": "15",
"year": "2021"
},
{
"DOI": "10.1002/em.22471",
"article-title": "Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: the special case of molnupiravir",
"author": "Waters",
"doi-asserted-by": "crossref",
"first-page": "37",
"journal-title": "Environ Mol Mutagen",
"key": "10.1016/S1473-3099(22)00507-2_bib47",
"volume": "63",
"year": "2022"
},
{
"DOI": "10.1093/infdis/jiab247",
"article-title": "β-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells",
"author": "Zhou",
"doi-asserted-by": "crossref",
"first-page": "415",
"journal-title": "J Infect Dis",
"key": "10.1016/S1473-3099(22)00507-2_bib48",
"volume": "224",
"year": "2021"
},
{
"DOI": "10.3390/ijms23073507",
"article-title": "Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease",
"author": "Mótyán",
"doi-asserted-by": "crossref",
"journal-title": "Int J Mol Sci",
"key": "10.1016/S1473-3099(22)00507-2_bib49",
"volume": "23",
"year": "2022"
}
],
"reference-count": 37,
"references-count": 37,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S1473309922005072"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [
"Infectious Diseases"
],
"subtitle": [],
"title": "Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy"
}
